Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 2/20 | 0.42 |
| ▸ | MAP2 | P11137 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353600 | 0.89 | CNR1 (0.52) | CNR1MAP2CYP19A1 | |
| SCHEMBL2344495 | 0.86 | MAP2 (0.54) | CNR1MAP2 | |
| SCHEMBL2349489 | 0.84 | MAP2 (0.52) | LMNACNR1MAP2MAPT | |
| SCHEMBL2346188 | 0.78 | MAP2 (0.49) | CNR1MEN1KMT2AMAP2HTT | |
| SCHEMBL2341743 | 0.78 | CNR1 (0.53) | CNR1MAP2 | |
| SCHEMBL2341414 | 0.77 | MAP2 (0.51) | CNR1MAP2 | |
| SCHEMBL2344487 | 0.77 | MAP2 (0.50) | CNR1GAAMAP2 | |
| SCHEMBL2350074 | 0.76 | MAP2 (0.50) | MAP2 | |
| SCHEMBL2344739 | 0.75 | MAP2 (0.49) | CNR1MAP2 | |
| SCHEMBL2351469 | 0.75 | MAP2 (0.51) | MAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | claimed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | claimed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | claimed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | claimed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | claimed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | LMNA 4845/4885HPGD 3749/4885CNR1 344/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | LMNA 4845/4885HPGD 3749/4885CNR1 344/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | LMNA 4845/4885HPGD 3749/4885CNR1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.